Colorectal Cancer Panel [NRAS, KRAS, BRAF] Test
Short Name: CRC Panel (NRAS, KRAS, BRAF)
Also known as: Colorectal Cancer Mutation Panel, KRAS NRAS BRAF Mutation Analysis, CRC Gene Panel
Colorectal Cancer Panel [NRAS, KRAS, BRAF] Test test available at DNA Labs India for ₹27,000. Uses Sanger Sequencing on Tumor tissue (paraffin-embedded block) samples. Results in Reports are typically available within 7-8 working days after the sample reaches the laboratory.. Free home collection in 300+ cities across India.
🩺 Medically Reviewed By
Dr Pasupathy Arumugam
Consultant Pathologist · Reg: 21521
Last reviewed: September 7, 2026
Overview
The purpose of this panel is to detect somatic mutations in NRAS, KRAS, and BRAF genes in colorectal cancer tissue. These mutations are predictive biomarkers for response to anti-EGFR therapy and prognostic indicators. The results help in: 1) Selecting patients who are likely to benefit from anti-EGFR inhibitors (wild-type KRAS/NRAS). 2) Avoiding ineffective therapy in patients with KRAS/NRAS mutations. 3) Identifying BRAF V600E mutation which has prognostic significance and may guide treatment with BRAF inhibitors in combination with other agents. 4) Providing molecular classification for clinical trials and personalized treatment planning.
- Test Code
- 6078
- CPT Code
- 81479
- ICD Code
- C18-C20
- Price
- ₹27,000
- Sample Type
- Tumor tissue (paraffin-embedded block)
- Result Time
- Reports are typically available within 7-8 working days after the sample reaches the laboratory.
- Fasting Required
- No
- Method
- Sanger Sequencing
Sample Collection
No special preparation required. A doctor's prescription is mandatory. Inform your healthcare provider about any medications you are taking.
Method: Surgical biopsy or resection specimen
Laboratory Analysis
The sample is a tumor tissue block obtained from a previous biopsy or surgery. No additional procedure is needed for the patient.
Report Delivery
No specific aftercare required. You can resume normal activities immediately.
Timeline: Reports are typically available within 7-8 working days after the sample reaches the laboratory.
Patient Instructions
About This Test
Who Should Get This Test
The purpose of this panel is to detect somatic mutations in NRAS, KRAS, and BRAF genes in colorectal cancer tissue. These mutations are predictive biomarkers for response to anti-EGFR therapy and prognostic indicators. The results help in: 1) Selecting patients who are likely to benefit from anti-EGFR inhibitors (wild-type KRAS/NRAS). 2) Avoiding ineffective therapy in patients with KRAS/NRAS mutations. 3) Identifying BRAF V600E mutation which has prognostic significance and may guide treatment with BRAF inhibitors in combination with other agents. 4) Providing molecular classification for clinical trials and personalized treatment planning.
How to Prepare
- Provide the paraffin-embedded tumor tissue block or unstained sections
- Ensure the block is properly labeled with patient identification
- Include a copy of the histopathology report if available
- Ship the sample in a leak-proof container at ambient temperature
Doctor's Notes
Reviewed by Dr Pasupathy Arumugam — MBBS, MD (Pathology) · Reg. No. 21521
"This panel is essential for selecting appropriate targeted therapies in metastatic colorectal cancer. Mutations in KRAS/NRAS predict resistance to anti-EGFR therapy, while BRAF V600E has prognostic and therapeutic implications."
Last medically reviewed: September 7, 2026
Test Parameters & Specifications
Sample Stability
- Inadequate tissue sample (less than 20% tumor content)
- Sample not in paraffin block or unstained slides
- Sample with extensive necrosis or autolysis
- Incorrect labeling or missing requisition form
- Sample received in inappropriate transport medium
Understanding Your Results
KRAS/NRAS mutation detected
Predicts lack of response to anti-EGFR therapy (cetuximab, panitumumab). Alternative treatment options should be considered.
KRAS/NRAS wild type (no mutation)
Patient may benefit from anti-EGFR therapy in combination with chemotherapy for metastatic colorectal cancer.
BRAF V600E mutation detected
Associated with poor prognosis. May benefit from BRAF inhibitor combinations (e.g., encorafenib + cetuximab).
BRAF wild type
No BRAF V600E mutation; standard treatment protocols apply.
Consult your oncologist to discuss the results and their implications for your treatment plan. Do not make any changes to your medication without medical advice.
Limitations
- ⚠This panel only detects mutations in the specified regions; other rare mutations may not be covered
- ⚠Sanger sequencing has a sensitivity of approximately 10-20% mutant allele frequency; low-level mutations may be missed
- ⚠Results are qualitative; not intended for quantitative measurement
- ⚠Test is performed on tumor tissue; it does not assess germline (inherited) mutations
- ⚠Clinical interpretation should be done in conjunction with histopathology and other molecular tests
Risks & Considerations
- ●No physical risks associated with this test as it is performed on an existing tissue sample
- ●Possible psychological distress from results
- ●Rare chance of inconclusive results requiring repeat testing
Interfering Factors
- ●Insufficient tumor content in the sample (<20%) may lead to false-negative results
- ●Decalcification of bone specimens may degrade DNA
- ●Fixation in acidic solutions or prolonged formalin exposure can cause DNA cross-linking
- ●Contamination with normal tissue may dilute mutant alleles
Compare With Similar Tests
| Test | Colorectal Cancer Panel [NRAS, KRAS, BRAF] | Colorectal Cancer Panel (KRAS, NRAS, BRAF, PIK3CA) | Colorectal Cancer Comprehensive Genomic Profiling (NGS) |
|---|---|---|---|
| Comparison | Colorectal Cancer Panel [NRAS, KRAS, BRAF] |
Frequently Asked Questions
What is the cost of the Colorectal Cancer Panel (NRAS, KRAS, BRAF) test?
What sample is required for this test?
Is fasting required before the test?
How long does it take to get the results?
What mutations are detected by this panel?
Why is this test important for colorectal cancer patients?
Can this test be done on a blood sample?
Is a doctor's prescription required?
Is home sample collection available?
What is the sensitivity of Sanger sequencing for this test?
Can this test be used for screening in healthy individuals?
What should I do if the result is 'mutation detected'?
Related Tests
Reference Laboratory Services
We serve as a reference laboratory for hospitals and clinics across India. Send samples from your facility with same-day pickup, priority processing, and results delivered through our online portal. Competitive institutional pricing available.
Your Data Privacy
Your medical data is protected under Indian law.
✓ Stored in India: All patient records are stored on servers located in India. No data is transferred outside the country.
✓ DPDP Act Compliant: Under the Digital Personal Data Protection Act 2023, you can request deletion of your records at any time by contacting support.
Book Your Test
Enter your details and we'll connect you within 15 minutes.